Bendamustine and Rituximab

DRUG3 trials

Sponsors

Cephalon, Czech CLL Study Group, International Extranodal Lymphoma Study Group (IELSG)

Conditions

Chronic Lymphocytic LeukemiaMarginal Zone B-cell LymphomaNon-Hodgkin's Lymphoma

Phase 2

SDX-105 in Combination With Rituxan for Patients With Relapsed Indolent or Mantle Cell Non-Hodgkin's Lymphoma (NHL)

CompletedNCT00076349

CephalonNon-Hodgkin's Lymphoma

Start: 2004-04-30End: 2008-03-31Updated: 2014-05-09

Bendamustine and Rituximab for the Treatment of Splenic Marginal Zone Lymphoma

CompletedNCT02853370

International Extranodal Lymphoma Study Group (IELSG)Marginal Zone B-cell Lymphoma

Start: 2012-07-31End: 2020-12-31Updated: 2023-02-01

Unknown Phase

Observational Study in CLL Patients Receiving BR

CompletedNCT02381899

Czech CLL Study GroupChronic Lymphocytic Leukemia

Start: 2014-09-30End: 2018-12-31Updated: 2019-02-01

Related Papers

FIRST APPLICATION OF MINIMAL RESIDUAL DISEASE ANALYSIS IN SPLENIC MARGINAL ZONE LYMPHOMA TRIALS: PRELIMINARY RESULTS FROM BRISMA/IELSG36 PHASE II STUDY

Hematological Oncology2019-06-017 citations

Prospective observational study in comorbid patients with chronic lymphocytic leukemia receiving first-line bendamustine with rituximab.

2019-02-156 citations